Clinical trials: Neoadjuvant Treatment
Sarcoma
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
- Trial name
- NCT03463408
- Testing
- nivolumab, ipilimumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Rochester
ESCC
Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
This study aims to explore the efficacy and safety of anlotinib combined with bemocizumab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with the goal of improving the pathological complete response…
- Trial name
- RAOS (NCT07627347)
- Testing
- anlotinib+bevacizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lung Neoplasms, Neoadjuvant Therapy
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy.
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07894458
- Testing
- Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Rectal Cancer
Prediction of the Response to Neoadjuvant Radiation Chemotherapy Through Texture Analysis Derived From Medical Imaging
In patient with complete pathological response, surgery could be omitted without compromising progression-free or overall survival. A powerful prediction model is needed to guide management of this population.
- Trial name
- RECTOMICS (NCT04920435)
- Where
- 3 sites in France
- Volunteers
- 124 people
- Sponsor
- University Hospital, Brest
Uterine Cervical Neoplasms
4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery
The investigators primary outcome was to evaluate the effectiveness in term of Overall Survival (OS) and disease free interval (DFI) of two different platinum-based chemotherapic regimen (3 and 6 cycles) for treatment of Locally…
- Trial name
- NCT02365935
- Testing
- Group A adjuvant chemotherapy, Group B adjuvant chemotherapy, Cisplatin
- Where
- Italy
- Volunteers
- 215 people
- Sponsor
- Campus Bio-Medico University
Breast Cancer
Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer
This study aimed to evaluate the feasibility of dual sentinel node staining method using mixture of indocyanine green(ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.
- Trial name
- NCT02168452
- Testing
- sentinel lymph node biopsy(SLNB)
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- National Cancer Center, Korea
Immunotherapy, Gastric Cancer (GC)
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Conditions
- Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
- Trial name
- NCT07165847
- Testing
- Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Small Cell Lung Cancer
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
EGFR-TKI has firmly established itself as a first-line treatment for advanced lung cancer with EGFR-sensitive mutations, and the ADAURA study has added to its indications for use as postoperative adjuvant therapy in early- and…
- Trial name
- NCT05987826
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Non Small Cell Lung Cancer
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
The primary aim of this single arm, phase II study is to determine the efficacy of the combination therapy Pembrolizumab/Lenvatinib regarding the rate of major pathological response (MPR-Rate).
- Trial name
- INNWOP1 (NCT04875585)
- Testing
- neoadjuvant therapy with Pembrolizumab/Lenvatinib, Surgery, Adjuvant Treatment Phase
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Medical University Innsbruck
Melanoma
Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
The main purpose of this study is to determine the rate of positive sentinel lymph nodes (i.e. the closest draining lymph node(s) to the primary melanoma site) and to test whether treatment with pembrolizumab before surgery to…
- Trial name
- NCT03757689
- Testing
- Pembrolizumab, Wide Excision and Sentinel Lymph Node (SLN) Biopsy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hypopharyngeal Cancer
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
The investigators will examine whether 2-cycles of DFP chemotherapy before definitive concurrent chemoradiation therapy (CCRT) can improve progression-free survival in locally advanced (Stage III \& IVM0) hypopharyngeal and base…
- Trial name
- NCT01312350
- Testing
- neoadjuvant docetaxel/cisplatin/fluorouracil, No treatment before definitive CCRT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Rectal Cancer
Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging
The purpose of this study is to determine whether whole-body MRI (WB-MRI) accuracy is superior to FDG-PET-CT considered as the gold-standard for the staging of distant lesions of rectal cancer.
- Trial name
- NCT01745874
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Lausanne Hospitals
Nasopharyngeal Cancer
Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study
Neoadjuvant chemotherapy followed by concurrent chemoradiation (CCRT) has been recommended in the treatment of locoregionally-advanced nasopharyngeal carcinoma (NPC), with docetaxel, cisplatin (DDP) and 5-fluorouracil (5-Fu)…
- Trial name
- NCT04850235
- Testing
- Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer
Metformin and Simvastatin Use in Bladder Cancer
A single arm, single center window of opportunity trial of using a combination of metformin and simvastatin as a neoadjuvant treatment for patients with invasive bladder cancer who are to undergo cystectomy.
- Trial name
- NCT02360618
- Testing
- Metformin, Simvastatin
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre
BRCA1 Mutation, Breast Cancer Invasive Nos
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland
This is a single center, non-randomized, open label phase II trial to evaluate the clinical and pathologic response of neoadjuvant cisplatin-monotherapy in BRCA1 positive patients.
- Trial name
- NCT01630226
- Testing
- Neoadjuvant Cisplatin Chemotherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-2 (NCT06588855)
- Testing
- Afimkibart
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 350 people
- Sponsor
- Hoffmann-La Roche
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Total neoadjuvant treatment (TNT) including radiotherapy and induction or consolidation systemic chemotherapy has become the standard treatment for patients with stage II and III rectal adenocarcinoma.
- Trial name
- PREDIR-NEOREC (NCT06762405)
- Testing
- radiotherapy, Dostarlimab, Biological study on circulating tumor DNA (optional for the patient)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
NSCLC
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for…
- Trial name
- VIGOR (NCT05583188)
- Testing
- Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Galvanize Therapeutics, Inc.
Breast Neoplasms
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
Prospective, monoinstitutional, phase II study. Patients with HER 2 positive locally advanced breast cancer will be treated with 3 initial cycles (12 weeks) of trastuzumab plus paclitaxel and then if responding further 12 weeks…
- Trial name
- NCT02307227
- Testing
- Trastuzumab, Paclitaxel, Epirubicin
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Early-stage Breast Cancer
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
In early breast cancer (eBC), pathological complete response (pCR) after neoadjuvant therapy acts as surrogate marker for metastasis and overall survival.
- Trial name
- NCT05332561
- Testing
- Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib
- Where
- 9 sites in Germany
- Volunteers
- 240 people
- Sponsor
- German Cancer Research Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.